| Previous Close | 33.36 |
| Open | 33.29 |
| Bid | 32.93 x 700 |
| Ask | 33.02 x 700 |
| Day's Range | 32.95 - 33.45 |
| 52 Week Range | 29.83 - 35.38 |
| Volume | 14,386,867 |
| Avg. Volume | 19,421,421 |
| Market Cap | 196.64B |
| Beta | 1.05 |
| PE Ratio (TTM) | 27.74 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.84%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Reuters•38 minutes ago
FDA approves Pfizer's drug for rare blood cancer
The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning. Besponsa was approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
- Zacks•7 hours ago
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.
- Market Realist•9 hours ago
How Amgen’s Nephrology Drugs Are Positioned after 2Q17?
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
